CNQ · BETR.CN
BetterLife Pharma Inc.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
Loading market information…
OTC · LIANY · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
LianMedical’s quoted price sits in the lower half of its reported 52-week range, 75.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
LianMedical’s forward annual dividend is $57.00 per share, paid monthly. The forward yield is 129,545.45% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
LianMedical’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$0.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow LianMedical’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for cholangiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 |
|---|
| Jun 29, 2022 |
| -$0.39 |
| $0.00 |
| Q4 2021 | Mar 30, 2022 | -$0.26+5.89% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
$0.01+$0.00 (+6.67%)
ProText Mobility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.07-$0.02 (-18.75%)
Inhibitor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
$0.10$0.00 (0.0%)
Quantum Genomics S.A.: Healthcare · Biotechnology.
$0.83+$0.06 (+8.02%)
Curative Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.32% below the high.
$0.00+$0.00 (+5.56%)
Univec, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.22% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$0.06+CA$0.01 (+10.0%)
PharmaTher Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.63% below the high.
